Wegovy 1.4 mg — where does this dose fit in your treatment?

Why 1.4 mg isn't part of the UK Wegovy schedule

The number 1.4 mg does appear in the world of semaglutide, it features in Ozempic's dosing sequence for type 2 diabetes. Ozempic is also semaglutide, also made by Novo Nordisk, but it carries a different licence: it's authorised for blood-sugar management in type 2 diabetes, not for weight management. Its titration path includes a 1 mg step that can be raised to 2 mg, and some international markets reference intermediate steps that include 1.4 mg. If you've spotted the figure in online forums or on packaging from an overseas supplier, that's almost certainly where it originates.

For weight management in the UK, Wegovy follows its own distinct schedule, as set out in the Summary of Product Characteristics and summarised by the NHS semaglutide medicines page. You can read more about how each step works, including what to expect at each stage, in our guide covering the full range of Wegovy mg strengths used in the UK schedule. The path is 0.25 mg (weeks 1–4), 0.5 mg (weeks 5–8), 1 mg (weeks 9–12), 1.7 mg (weeks 13–16), and 2.4 mg from week 17 onward as the maintenance dose. There is no 1.4 mg rung on that ladder. Mixing up the two products' dose schedules is a genuine clinical risk, one more reason why sourcing semaglutide from informal or unverified channels, and self-adjusting doses, can cause real harm.

If your current dose feels too high or you're struggling with side effects at a particular level, the right move is a conversation with your prescriber, not a halfway dose you've read about online. That's precisely what clinical aftercare exists for.

The decision most people are actually facing at this point in treatment

Readers searching for 1.4 mg are usually at a specific crossroads: they're somewhere between 1 mg and the next licensed step, and they're trying to work out whether to push forward, hold steady, or step back. That's a real and reasonable question. The full Wegovy dose guide covers the schedule in detail, but the core principle is straightforward: titration exists to give your body time to adjust.

Nausea, loose stools, and reduced appetite are most noticeable in the first few days after a dose increase, and they typically ease within a couple of weeks for most people. If they don't, or if they feel unmanageable, a prescriber can recommend staying at your current dose for an extra four weeks before moving up. Our page on Wegovy 1 mg explains what that particular stage of treatment involves and what it typically feels like to hold at that step. What it isn't is splitting a dose or using a quantity your prescriber hasn't agreed.

Some people also reach this search after reading about the higher 7.2 mg dose approved by the MHRA in 2026. Understanding what changes at 2.4 mg (the standard maintenance level) is often more relevant to where most patients are in their journey than any intermediate figure.

Side effects to be aware of as doses increase

The GI side effects that come with dose increases (nausea, vomiting, constipation, reflux, tiredness) are the body's predictable response to more semaglutide. They usually peak in the first week of a new dose and settle. Keeping the pen in the fridge door as a prompt for the same day each week helps with consistency, which in turn helps with tolerability.

Less common but more serious effects require prompt attention. In January 2026, the MHRA issued a Drug Safety Update flagging acute pancreatitis as a known, infrequent but potentially serious effect of GLP-1 medicines: severe, persistent stomach pain, especially if it radiates to the back, warrants urgent medical help. Gallbladder problems and signs of dehydration after persistent vomiting are also worth acting on quickly rather than waiting out.

Reporting unexpected reactions matters, both to your prescriber and, if appropriate, through the MHRA Yellow Card scheme, which is open to patients as well as healthcare professionals. The nume frequently asked questions page covers what to do if you're unsure whether a symptom is serious.

Getting the right dose through a proper clinical process

The most common frustration we hear is not about a specific dose, it's about not having anyone to ask. Whether that's a long NHS waiting list, a GP who isn't prescribing Wegovy yet, or a previous online service that dispatched pens without much follow-up, the pattern is the same: the medicine arrived, but the clinical support didn't.

Semaglutide for weight management is a prescription-only medicine. That means a registered prescriber reviews your case before every prescription is issued, initial consultation, and every repeat. At nume, that review is carried out the same day by a real clinician, not automated software. There's more on how the process works on the about us page, and if cost is a factor in your thinking, the Wegovy cost guide sets out what a legitimate private prescription realistically involves. The short version: one transparent price, no subscription, no hidden fees. If you're ready to explore whether Wegovy is clinically right for you, start your free consultation and a prescriber will review your answers the same day.